Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DLX 105

Drug Profile

DLX 105

Alternative Names: DLX-105; ESBA-105; Humanised single-chain (scFv) antibody directed against human TNF-alpha

Latest Information Update: 11 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ESBATech
  • Developer Delenex Therapeutics; ESBATech; Kuur Therapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Immunoglobulin fragments
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Behcet's syndrome; Crohn's disease; Dry eyes; Hidradenitis suppurativa; Ocular inflammation; Osteoarthritis; Plaque psoriasis; Uveitis

Most Recent Events

  • 04 May 2021 Kuur Therapeutics has been acquired by Athenex
  • 13 Mar 2020 Cell Medica is now called Kuur Therapeutics
  • 09 Apr 2019 Novartis completed the spin-off of Alcon
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top